1. Home
  2. CBL vs XERS Comparison

CBL vs XERS Comparison

Compare CBL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBL & Associates Properties Inc.

CBL

CBL & Associates Properties Inc.

N/A

Current Price

$37.82

Market Cap

1.1B

Sector

Real Estate

ML Signal

N/A

XERS

Xeris Biopharma Holdings Inc.

N/A

Current Price

$6.61

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CBL
XERS
Founded
1978
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
CBL
XERS
Price
$37.82
$6.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$45.00
$10.43
AVG Volume (30 Days)
156.9K
1.4M
Earning Date
05-18-2026
03-26-2026
Dividend Yield
4.76%
N/A
EPS Growth
1000.00
17.78
EPS
2.78
N/A
Revenue
$515,561,000.00
$49,590,000.00
Revenue This Year
N/A
$44.77
Revenue Next Year
N/A
$27.72
P/E Ratio
$13.63
N/A
Revenue Growth
N/A
142.67
52 Week Low
$21.10
$3.59
52 Week High
$38.67
$10.08

Technical Indicators

Market Signals
Indicator
CBL
XERS
Relative Strength Index (RSI) 57.88 38.62
Support Level $34.52 $4.30
Resistance Level $38.59 $8.43
Average True Range (ATR) 1.10 0.30
MACD 0.23 -0.04
Stochastic Oscillator 80.33 33.15

Price Performance

Historical Comparison
CBL
XERS

About CBL CBL & Associates Properties Inc.

CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Share on Social Networks: